Clinical Takeaway
In this randomized, double-blind, placebo-controlled crossover trial in healthy males, neither a low nor a high single dose of CBD produced measurable changes in cortical excitability compared to placebo. This suggests CBD may not have direct intrinsic anti-epileptic activity on its own, and its clinical benefits in seizure disorders like Dravet syndrome and Lennox-Gastaut Syndrome likely depend on its pharmacokinetic interaction with clobazam rather than a standalone neurological effect.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure management may depend primarily on drug-drug interactions with concurrent antiepileptic medications rather than direct effects on neuronal excitability, which has significant implications for understanding its mechanism of action and optimizing polypharmacy strategies. The finding that CBD lacks direct cortical effects challenges assumptions about how this FDA-approved agent works and suggests clinicians should reconsider dosing strategies and patient selection, particularly in monotherapy scenarios where such interactions would not occur. Understanding these pharmacokinetic rather than pharmacodynamic mechanisms is essential for predicting efficacy in different clinical populations and avoiding ineffective treatment regimens.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This well-designed crossover study challenges a common assumption about CBD’s mechanism in seizure management by demonstrating that CBD does not directly suppress cortical excitability in the way traditional antiepileptic drugs do, suggesting its clinical benefit in Dravet and Lennox-Gastaut syndromes may arise primarily through pharmacokinetic interactions with concurrent medications like clobazam rather than direct neurophysiologic effects. While the study’s rigorous methodology is reassuring, clinicians should recognize that lack of direct cortical suppression does not negate CBD’s clinical utility in these severe pediatric epilepsies, and individual patient responses may still vary based on complex drug-drug interactions and metabolic factors. The findings reinforce that we should not assume CBD works like conventional anticonvulsants and highlight the importance of monitoring coadministered medications when prescribing it. Going forward, practitioners using CBD for seizure disorders should continue to carefully assess seizure control and medication interactions rather than relying on CBD as monotherapy for